5 drugs in shortage
Here are five new drug shortages and discontinuations, according to drug supply databases from the FDA and the American Society of Health-System Pharmacists.
- Bumetanide injection: Several manufacturers, including Fresenius Kabi, Hikma Pharmaceuticals, Novadoz Pharmaceuticals and Sagent Pharmaceuticals have reported a shortage of bumetanide injection, a cardiovascular drug used as a loop diuretic. The affected strength is 0.25 milligram/1 milliliter.
- Dopamine hydrochloride injection: Hospira has discontinued its dopamine hydrochloride in dextrose 5% injection, a cardiovascular medication used to treat shock and heart failure. The discontinued presentation is 800 milligram/500 milliliter.
- Dobutamine hydrochloride injection: Pfizer has discontinued its 12.5 milligram/1 milliliter strength of dobutamine hydrochloride injection, a cardiovascular drug often used in acute heart failure and shock.
- Methylprednisolone acetate injection: Multiple presentations of methylprednisolone acetate injection, a corticosteroid used to treat inflammation, are currently in shortage. Affected products include Pfizer’s Depo Medrol in 40- and 80-milligram/milliliter strengths, Eugia’s 40-milligram/milliliter vials and Sandoz’s 40- and 80-milligram/milliliter vials. The shortage is due to manufacturing delays and increased demand. Resupply dates range from September to November 2025.
- Sodium ferric gluconate complex injection: Sodium ferric gluconate complex in sucrose injection, used to treat iron deficiency anemia, is in shortage. Affected manufacturers include Sanofi-Aventis and Hikma. Both companies have placed the 62.5-milligram/5 milliliter vials on allocation, and no reason for shortage was provided.
The post 5 drugs in shortage appeared first on Becker’s Hospital Review | Healthcare News & Analysis.